NASDAQ: MDGL
Madrigal Pharmaceuticals Inc Stock

$333.91-6.89 (-2.02%)
Updated Apr 30, 2025
MDGL Price
$333.91
Fair Value Price
$166.09
Market Cap
$7.37B
52 Week Low
$200.08
52 Week High
$377.46
P/E
-15.25x
P/B
9.77x
P/S
36.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$180.13M
Earnings
-$465.89M
Gross Margin
96.5%
Operating Margin
-250.49%
Profit Margin
-258.6%
Debt to Equity
0.38
Operating Cash Flow
-$456M
Beta
0.78
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A

MDGL Overview

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine MDGL's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
MDGL
Ranked
#99 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important MDGL news, forecast changes, insider trades & much more!

MDGL News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MDGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MDGL ($333.91) is overvalued by 101.04% relative to our estimate of its Fair Value price of $166.09 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MDGL ($333.91) is not significantly undervalued (101.04%) relative to our estimate of its Fair Value price of $166.09 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MDGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MDGL due diligence checks available for Premium users.

Valuation

MDGL fair value

Fair Value of MDGL stock based on Discounted Cash Flow (DCF)

Price
$333.91
Fair Value
$166.09
Overvalued by
101.04%
MDGL ($333.91) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MDGL ($333.91) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MDGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

MDGL price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-15.25x
Industry
-162.28x
Market
29.18x

MDGL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
9.77x
Industry
4.45x
MDGL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MDGL's financial health

Profit margin

Revenue
$103.3M
Net Income
-$59.4M
Profit Margin
-57.5%
MDGL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MDGL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.0B
Liabilities
$287.9M
Debt to equity
0.38
MDGL's short-term assets ($1.03B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDGL's short-term assets ($1.03B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDGL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MDGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$104.5M
Investing
-$48.0M
Financing
$19.8M
MDGL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MDGL vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
MDGLC$7.37B-2.02%-15.25x9.77x
BBIOD$7.28B+5.33%-10.81x-4.42x
RVMDF$7.51B-0.71%-11.28x3.31x
HALOB$7.56B+0.99%17.55x20.79x
CORTC$7.58B-1.84%53.24x11.16x

Madrigal Pharmaceuticals Stock FAQ

What is Madrigal Pharmaceuticals's quote symbol?

(NASDAQ: MDGL) Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol MDGL. Madrigal Pharmaceuticals stock quotes can also be displayed as NASDAQ: MDGL.

If you're new to stock investing, here's how to buy Madrigal Pharmaceuticals stock.

What is the 52 week high and low for Madrigal Pharmaceuticals (NASDAQ: MDGL)?

(NASDAQ: MDGL) Madrigal Pharmaceuticals's 52-week high was $377.46, and its 52-week low was $200.08. It is currently -11.54% from its 52-week high and 66.89% from its 52-week low.

How much is Madrigal Pharmaceuticals stock worth today?

(NASDAQ: MDGL) Madrigal Pharmaceuticals currently has 22,080,246 outstanding shares. With Madrigal Pharmaceuticals stock trading at $333.91 per share, the total value of Madrigal Pharmaceuticals stock (market capitalization) is $7.37B.

Madrigal Pharmaceuticals stock was originally listed at a price of $318.15 in Feb 6, 2007. If you had invested in Madrigal Pharmaceuticals stock at $318.15, your return over the last 18 years would have been 4.95%, for an annualized return of 0.27% (not including any dividends or dividend reinvestments).

How much is Madrigal Pharmaceuticals's stock price per share?

(NASDAQ: MDGL) Madrigal Pharmaceuticals stock price per share is $333.91 today (as of Apr 30, 2025).

What is Madrigal Pharmaceuticals's Market Cap?

(NASDAQ: MDGL) Madrigal Pharmaceuticals's market cap is $7.37B, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Madrigal Pharmaceuticals's market cap is calculated by multiplying MDGL's current stock price of $333.91 by MDGL's total outstanding shares of 22,080,246.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.